IP Library Granted Patent US 8,642,662
Granted Patent B2
US 8,642,662 · App. 13/481,584 · Granted Feb 4, 2014

Methods of using derivatives of (−)-venlafaxine

Inventors: Thomas P. Jerussi (Framingham, MA); Chrisantha H. Senanayake (Shrewsbury, MA); Nandkumar N. Bhongle (Shrewsbury, MA)
Assignee: Sunovion Pharmaceuticals Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,642,662
App. No.
13/481,584
Granted
Feb 4, 2014
Kind
B2
Abstract

Methods of preparing, and compositions comprising, derivatives of (−)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.

Claims (5)

1. A method of treating bipolar and manic conditions comprising administering to a human a therapeutically effective amount of a (−)-venlafaxine derivative, or a pharmaceutically acceptable salt thereof, wherein the (−)-venlafaxine derivative comprises less than 10% by weight of its (+) stereoisomer.

2. The method of claim 1 , wherein the (−) venlafaxine derivative is (−)-O-desmethylvenlafaxine, (−)-N-desmethylvenlafaxine, (−)-N,O-didesmethylvenlafaxine, (−)-N,N-didesmethylvenlafaxine, or (−)-O-desmethyl-N,N-didesmethylvenlafaxine.

3. The method of claim 2 , wherein the (−)-venlafaxine derivative is (−)-O-desmethylvenlafaxine.

4. The method of claim 1 , wherein the (−)-venlafaxine derivative comprises less than 5% by weight of its (+) stereoisomer.

5. The method of claim 1 , wherein the (−)-venlafaxine derivative comprises less than 1% by weight of its (+) stereoisomer.

Continuity (7)
Continuation 11418138 · May 5, 2006
Division 10806423 · Mar 23, 2004
Division 10222815 · Aug 19, 2002
Division 10014592 · Dec 14, 2001
Division 09450690 · Nov 30, 1999
Provisional Application 60110488 · Dec 1, 1998
Related Publication 20120232157A1 · Sep 13, 2012